Source: Annual Congress 2006 - Miscellaneous respiratory infections I
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
F. Sanz, J. Blanquer, M. L. Briones, E. Fernández, E. Martínez, C. Ferrando (Valencia, Spain). Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy. Eur Respir J 2006; 28: Suppl. 50, 4227

Member's Comments

No comment yet.

Related content which might interest you: Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 Potential protective role of prior to diagnosis antibiotic treatment in community-acquired pneumonia: Clinical presentation and outcomes Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Predictor factors of empirical antimicrobial treatment failure in community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 357s Year: 2002 Appropriateness and delay to initiate therapy in ventilator-associated pneumonia Source: Eur Respir J 2006; 27: 158-164 Year: 2006 Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet? Source: Eur Respir J 2013; 41: 5-6 Year: 2013 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis Source: Eur Respir J 2012; 39: 611-618 Year: 2012 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning Source: Eur Respir J, 54 (6) 1900824; 10.1183/13993003.00824-2019 Year: 2019 Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia Source: Eur Respir J 2007; 30: 1234-1235 Year: 2007 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Early outcomes in CAP: clinical stability, clinical failure and nonresolving pneumonia Source: Eur Respir Monogr 2014; 63: 205-218 Year: 2014 Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012